Thomas Fekete, MD, MACP, Thomas Durant Chair and Professor of Medicine and Professor of Microbiology and Immunology at the Lewis Katz School of Medicine at Temple University, offered insight to WHYY about Merck’s new drug molnupiravir, which could be the first pill to treat COVID-19. Merck has asked the U.S. Food and Drug Administration to authorize the treatment.
Important announcement concerning Temple Health and Keystone First. Our provider agreement with Keystone First is scheduled to end on July 31st. Click the link below to learn about your options for continuing care at Temple Health.
Learn More
800-TEMPLE-MED
Schedule Appointment
SEARCH TEMPLE HEALTH
Related News
Philadelphia Media Outlets Cover Important Announcement Concerning Temple Health and Keystone First Family Health Plans
Posted July 10, 2024Temple Health’s (providers and hospitals) provider agreement with health insurance company Keystone First Family Health Plans is scheduled to end on July 31st.
Read MoreMoves in Medicine: Dr. Charles Bakhos and Patient Discuss Diaphragm Paralysis
Posted July 8, 20246ABC-TV and Temple Health collaborated on a sponsored segment about diaphragm paralysis. The segment featured Dr. Charles Bakhos and a patient.
Read More